What are the benefits of Levodropropizine Buccal Tablets?

Levodropropizine Buccal Tablets are indicated for the treatment of dry cough and persistent cough caused by acute upper respiratory infections and acute bronchitis.

Levodropropizine Buccal Tablets are peripheral antitussive drugs. They exert antitussive effects through peripheral selective inhibition of neuropeptides contained in C-fibers of the trachea and bronchi. Their site of action is located at peripheral postsynaptic sites related to sensory neuropeptides. They have strong antitussive effects with long-lasting duration. Since they have no effects on β-adrenergic receptors, M-cholinergic receptors, and opioid receptors, they have fewer adverse reactions related to central inhibition, making them an effective and safe antitussive medication. They are suitable for the treatment of dry cough and persistent cough caused by acute upper respiratory infections and acute bronchitis.

Levodropropizine Buccal Tablets may cause gastrointestinal reactions such as nausea, epigastric pain, indigestion, vomiting, and diarrhea. Some individuals may also experience central nervous system reactions such as fatigue, dizziness, drowsiness, headache, palpitations, and dry mouth. Occasionally, visual disturbances and rashes may occur. Transient elevations in aminotransferase levels may be observed with high-dose administration.

1. This medication is contraindicated in patients with known or suspected hypersensitivity to this class of drugs.

2. It is contraindicated in patients with excessive mucus production or impaired mucociliary clearance.

3. It is contraindicated in pregnant and lactating women.